Product
TAS1553
1 clinical trial
3 indications
Indication
Acute Myeloid LeukemiaIndication
Myeloproliferative NeoplasmClinical trial
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsStatus: Terminated, Estimated PCD: 2023-02-20